Status:
COMPLETED
Radiotherapy in Primary Mediastinal Lymphoma
Lead Sponsor:
Instituto Mexicano del Seguro Social
Conditions:
Adjuvant Radiotherapy on Complete Remission Patients
Eligibility:
All Genders
18-65 years
Brief Summary
The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treate...
Eligibility Criteria
Inclusion
- Diagnosis of primary mediastinal lymphoma No previous treatment performance status \< 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function
Exclusion
- pregnancy
- \-
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
198 Patients enrolled
Trial Details
Trial ID
NCT01230008
Start Date
June 1 2002
End Date
December 1 2009
Last Update
October 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Research Unit
Mèxico DF, Mexico City, Mexico, 06725